Get the Stockscreener App
65.00
1.05%
-0.69
After Hours:
65.23
0.23
+0.35%
Arrowhead Pharmaceuticals Inc stock is traded at $65.00, with a volume of 6.97M.
It is down -1.05% in the last 24 hours and down -5.25% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$65.69
Open:
$67.32
24h Volume:
6.97M
Relative Volume:
2.78
Market Cap:
$8.83B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-46.76
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-2.09%
1M Performance:
-5.25%
6M Performance:
+270.58%
1Y Performance:
+229.11%
1-Day Range:
$64.55
$69.42
1-Week Range:
$60.62
$76.76
52-Week Range:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.00 | 8.93B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
How Arrowhead Pharmaceuticals Inc. (HDP1) stock moves in volatile trading sessions2025 Dividend Review & AI Driven Stock Price Forecasts - ulpravda.ru
Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsideShare Buyback & Risk Managed Investment Signals - ulpravda.ru
ARWR: Joint Management by Jefferies and JPMorgan in Recent Offering - GuruFocus
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - BioSpace
Arrowhead Pharmaceuticals (ARWR) Unveils $625M Convertible Notes Offering - GuruFocus
Arrowhead Pharmaceuticals prices $625 million convertible notes offering - Investing.com
ARWR: Goldman Sachs Raises Arrowhead Pharma's Price Target to $8 - GuruFocus
Arrowhead Pharma (ARWR) Sees Target Price Boost by Morgan Stanley | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals shares down 7.8% after co announces stock sale, convertible bond offering - MarketScreener
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Bernstein reiterates Market Perform rating on Arrowhead Pharma stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Gains Approval in China for Red - GuruFocus
Arrowhead Pharma stock rating reiterated by Cantor Fitzgerald on obesity data - Investing.com Canada
Chardan Capital Raises Price Target for Arrowhead Pharma (ARWR) to $80.00 | ARWR Stock News - GuruFocus
Arrowhead (ARWR) Gains Approval in China for Redemplo - GuruFocus
Sanofi launches plozasiran in China following NMPA approval By Investing.com - Investing.com Australia
Sanofi launches plozasiran in China following NMPA approval - Investing.com
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial - Clinical Trials Arena
Arrowhead Pharma stock holds steady as Goldman Sachs maintains Neutral rating - Investing.com Canada
Arrowhead Pharma stock price target raised to $84 from $81 at BofA - Investing.com UK
Arrowhead Pharmaceuticals plans to offer $700 million in securities By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences - FinancialContent
Arrowhead Pharmaceuticals (ARWR) Surges on Promising Obesity The - GuruFocus
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Arrowhead (ARWR) Plans Convertible Notes and Stock Offerings - GuruFocus
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - TradingView — Track All Markets
Arrowhead Pharmaceuticals Shares Surge on Health Canada Approval - StocksToTrade
Arrowhead Shoots For Obesity With RNAi, Shows Weight Loss Success - Citeline News & Insights
Arrowhead Pharmaceuticals Announces Interim Results from Obesity Treatment Trials - TradingView — Track All Markets
Arrowhead Pharmaceuticals: A Closer Look at the Recent Stock Activity - StocksToTrade
Arrowhead Pharmaceuticals: More Questions Than Answers After Obesity Data Update - Seeking Alpha
Arrowhead (ARWR) Stock Gains from Promising Drug Trial Results - GuruFocus
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss - ts2.tech
Arrowhead Pharmaceuticals Gains as Health Canada Approves Redemplo - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week HighTime to Buy? - MarketBeat
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study - BioSpace
Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR) - MarketBeat
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials - Benzinga
Arrowhead Pharmaceuticals stock hits 52-week high at $72.95 By Investing.com - Investing.com Nigeria
Arrowhead’s RNAi trims fat in early PhI/IIa obesity data - The Pharma Letter
Arrowhead (ARWR) Reveals Promising Interim Results in Obesity Tr - GuruFocus
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition - BioSpace
Arrowhead gains as obesity therapy doubles weight loss with Lilly’s Zepbound (ARWR:NASDAQ) - Seeking Alpha
Arrowhead stock soars after obesity drug shows doubled weight loss By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals announces interim clinical data on RNAi-based obesity candidates - MarketScreener
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS - Yahoo Finance
Arrowhead Pharma Shares in Focus After $2.5M Insider Sale - Eudaimonia and Co
Arrowhead Pharmaceuticals (ARWR) Is Down 5.0% After First-in-Class FCS siRNA Approval in Canada - Yahoo Finance
Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 13,187 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):